Effect of hydrosoluble vitamin E on erythrocyte membrane lipid composition in patients with advanced cirrhosis: An open-label pilot trial

Sophie Restellini, Mahnaz Alaei, Thomas Matthes, Omar Kherad, Antonio Moschetta, Laurent Spahr

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Aim: Deficiency in vitamin E, a natural antioxidant, participates in abnormal erythrocyte membrane lipids, structural alterations and hemolysis in advanced cirrhosis. Poor absorption of fat-soluble vitamins limits full correction of deficiency with standard formulations in cirrhosis with cholestasis. The aim of the present study was to examine safety and effects of tocofersolan, a water-soluble derivative of vitamin E, on erythrocyte membrane lipids and anemia in patients with biopsy-proven advanced cirrhosis, vitamin E deficiency and hemolysis. Methods: Twenty patients (age, 53±10 years; Child class B/C, 8/12), with low plasma vitamin E, chronic anemia and hemolysis, received oral tocofersolan 700mg/day for 4 weeks. Erythrocyte membrane lipid composition (cholesterol [Chol], phospholipids [Phosph]) was determined by enzymatic assays. Total and conjugated bilirubin, hemoglobin and vitamin E were measured. Results: Abdominal pain occurred in one patient. Five patients received blood transfusions due to severe anemia. After 4 weeks, both Chol and Phosph decreased, but changes were not significant. Both plasma vitamin E (P<0.05) and hemoglobin (P<0.05) increased, together with a decrease in total (P<0.05) and conjugated (P<0.05) bilirubin. Conclusion: In patients with advanced cirrhosis, low vitamin E plasma levels and chronic anemia with hemolysis, oral tocofersolan was overall well tolerated, but did not affect erythrocyte membrane lipid composition.

Original languageEnglish (US)
Pages (from-to)890-897
Number of pages8
JournalHepatology Research
Volume45
Issue number8
DOIs
StatePublished - Aug 1 2015

Fingerprint

Erythrocyte Membrane
Membrane Lipids
Vitamin E
Hemolysis
Fibrosis
Anemia
Vitamin E Deficiency
Bilirubin
Phospholipids
Abnormal Erythrocytes
Hemoglobin E
Cholesterol
Cholestasis
Enzyme Assays
Vitamins
Blood Transfusion
Abdominal Pain
Antioxidants
Fats
Biopsy

Keywords

  • Acanthocytosis
  • Anemia
  • Cirrhosis
  • Erythrocyte membrane
  • Hemolysis
  • Vitamin E

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Effect of hydrosoluble vitamin E on erythrocyte membrane lipid composition in patients with advanced cirrhosis : An open-label pilot trial. / Restellini, Sophie; Alaei, Mahnaz; Matthes, Thomas; Kherad, Omar; Moschetta, Antonio; Spahr, Laurent.

In: Hepatology Research, Vol. 45, No. 8, 01.08.2015, p. 890-897.

Research output: Contribution to journalArticle

Restellini, Sophie ; Alaei, Mahnaz ; Matthes, Thomas ; Kherad, Omar ; Moschetta, Antonio ; Spahr, Laurent. / Effect of hydrosoluble vitamin E on erythrocyte membrane lipid composition in patients with advanced cirrhosis : An open-label pilot trial. In: Hepatology Research. 2015 ; Vol. 45, No. 8. pp. 890-897.
@article{ea625f93ff6747a8aa35db3cfbbf81b2,
title = "Effect of hydrosoluble vitamin E on erythrocyte membrane lipid composition in patients with advanced cirrhosis: An open-label pilot trial",
abstract = "Aim: Deficiency in vitamin E, a natural antioxidant, participates in abnormal erythrocyte membrane lipids, structural alterations and hemolysis in advanced cirrhosis. Poor absorption of fat-soluble vitamins limits full correction of deficiency with standard formulations in cirrhosis with cholestasis. The aim of the present study was to examine safety and effects of tocofersolan, a water-soluble derivative of vitamin E, on erythrocyte membrane lipids and anemia in patients with biopsy-proven advanced cirrhosis, vitamin E deficiency and hemolysis. Methods: Twenty patients (age, 53±10 years; Child class B/C, 8/12), with low plasma vitamin E, chronic anemia and hemolysis, received oral tocofersolan 700mg/day for 4 weeks. Erythrocyte membrane lipid composition (cholesterol [Chol], phospholipids [Phosph]) was determined by enzymatic assays. Total and conjugated bilirubin, hemoglobin and vitamin E were measured. Results: Abdominal pain occurred in one patient. Five patients received blood transfusions due to severe anemia. After 4 weeks, both Chol and Phosph decreased, but changes were not significant. Both plasma vitamin E (P<0.05) and hemoglobin (P<0.05) increased, together with a decrease in total (P<0.05) and conjugated (P<0.05) bilirubin. Conclusion: In patients with advanced cirrhosis, low vitamin E plasma levels and chronic anemia with hemolysis, oral tocofersolan was overall well tolerated, but did not affect erythrocyte membrane lipid composition.",
keywords = "Acanthocytosis, Anemia, Cirrhosis, Erythrocyte membrane, Hemolysis, Vitamin E",
author = "Sophie Restellini and Mahnaz Alaei and Thomas Matthes and Omar Kherad and Antonio Moschetta and Laurent Spahr",
year = "2015",
month = "8",
day = "1",
doi = "10.1111/hepr.12430",
language = "English (US)",
volume = "45",
pages = "890--897",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Effect of hydrosoluble vitamin E on erythrocyte membrane lipid composition in patients with advanced cirrhosis

T2 - An open-label pilot trial

AU - Restellini, Sophie

AU - Alaei, Mahnaz

AU - Matthes, Thomas

AU - Kherad, Omar

AU - Moschetta, Antonio

AU - Spahr, Laurent

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Aim: Deficiency in vitamin E, a natural antioxidant, participates in abnormal erythrocyte membrane lipids, structural alterations and hemolysis in advanced cirrhosis. Poor absorption of fat-soluble vitamins limits full correction of deficiency with standard formulations in cirrhosis with cholestasis. The aim of the present study was to examine safety and effects of tocofersolan, a water-soluble derivative of vitamin E, on erythrocyte membrane lipids and anemia in patients with biopsy-proven advanced cirrhosis, vitamin E deficiency and hemolysis. Methods: Twenty patients (age, 53±10 years; Child class B/C, 8/12), with low plasma vitamin E, chronic anemia and hemolysis, received oral tocofersolan 700mg/day for 4 weeks. Erythrocyte membrane lipid composition (cholesterol [Chol], phospholipids [Phosph]) was determined by enzymatic assays. Total and conjugated bilirubin, hemoglobin and vitamin E were measured. Results: Abdominal pain occurred in one patient. Five patients received blood transfusions due to severe anemia. After 4 weeks, both Chol and Phosph decreased, but changes were not significant. Both plasma vitamin E (P<0.05) and hemoglobin (P<0.05) increased, together with a decrease in total (P<0.05) and conjugated (P<0.05) bilirubin. Conclusion: In patients with advanced cirrhosis, low vitamin E plasma levels and chronic anemia with hemolysis, oral tocofersolan was overall well tolerated, but did not affect erythrocyte membrane lipid composition.

AB - Aim: Deficiency in vitamin E, a natural antioxidant, participates in abnormal erythrocyte membrane lipids, structural alterations and hemolysis in advanced cirrhosis. Poor absorption of fat-soluble vitamins limits full correction of deficiency with standard formulations in cirrhosis with cholestasis. The aim of the present study was to examine safety and effects of tocofersolan, a water-soluble derivative of vitamin E, on erythrocyte membrane lipids and anemia in patients with biopsy-proven advanced cirrhosis, vitamin E deficiency and hemolysis. Methods: Twenty patients (age, 53±10 years; Child class B/C, 8/12), with low plasma vitamin E, chronic anemia and hemolysis, received oral tocofersolan 700mg/day for 4 weeks. Erythrocyte membrane lipid composition (cholesterol [Chol], phospholipids [Phosph]) was determined by enzymatic assays. Total and conjugated bilirubin, hemoglobin and vitamin E were measured. Results: Abdominal pain occurred in one patient. Five patients received blood transfusions due to severe anemia. After 4 weeks, both Chol and Phosph decreased, but changes were not significant. Both plasma vitamin E (P<0.05) and hemoglobin (P<0.05) increased, together with a decrease in total (P<0.05) and conjugated (P<0.05) bilirubin. Conclusion: In patients with advanced cirrhosis, low vitamin E plasma levels and chronic anemia with hemolysis, oral tocofersolan was overall well tolerated, but did not affect erythrocyte membrane lipid composition.

KW - Acanthocytosis

KW - Anemia

KW - Cirrhosis

KW - Erythrocyte membrane

KW - Hemolysis

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=84937518600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937518600&partnerID=8YFLogxK

U2 - 10.1111/hepr.12430

DO - 10.1111/hepr.12430

M3 - Article

C2 - 25286983

AN - SCOPUS:84937518600

VL - 45

SP - 890

EP - 897

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 8

ER -